Background: Despite a high nonresponse rate, predictors of response to anti-tumor necrosis factor (anti-TNF) therapy in ulcerative colitis (UC) remain limited. We aim to determine clinical and genetic predictors of primary nonresponse (PNR) and durable response (DR) to anti-TNF therapy in a large prospective UC cohort. Methods: Using the Illumina Immunochip, candidate polymorphisms associated with clinical outcomes of PNR and DR were separately evaluated and combined into weighted genetic risk scores. Combined genetic and clinical multivariable models for PNR and DR were compared with clinical predictive models using area under the receiver operating characteristic (AUROC) curves. Models were internally (DR) or externally (PNR) validated. Multivariable logistic regression was utilized to assess the association of genetic risk scores with infliximab levels and antibodies. Results: Of 231 patients, 28 (12%) experienced PNR and 120 (52%) experienced DR. There was no significant difference in clinical features between primary nonresponders and responders. Eight alleles were associated with PNR. A combined clinical-genetic model (AUROC, 0.87) more accurately predicted PNR compared with a clinical-only model (AUROC, 0.57; P < 0.0001). In an external cohort of 131 patients, increasing tertiles of PNR genetic risk score correlated with increased risk of PNR (P = 0.052). Twelve candidate loci were associated with DR. Genetic risk score quartiles for DR demonstrated a strong dose-response relationship in predicting treatment duration. Genetic risk scores for PNR and DR were not associated with infliximab levels or antibody formation. Conclusion: Genetic polymorphisms enhance prediction of PNR and DR to anti-TNF therapy in patients with UC.
Background: Despite a high nonresponse rate, predictors of response to anti-tumor necrosis factor (anti-TNF) therapy in ulcerative colitis (UC) remain limited. We aim to determine clinical and genetic predictors of primary nonresponse (PNR) and durable response (DR) to anti-TNF therapy in a large prospective UC cohort. Methods: Using the Illumina Immunochip, candidate polymorphisms associated with clinical outcomes of PNR and DR were separately evaluated and combined into weighted genetic risk scores. Combined genetic and clinical multivariable models for PNR and DR were compared with clinical predictive models using area under the receiver operating characteristic (AUROC) curves. Models were internally (DR) or externally (PNR) validated. Multivariable logistic regression was utilized to assess the association of genetic risk scores with infliximab levels and antibodies. Results: Of 231 patients, 28 (12%) experienced PNR and 120 (52%) experienced DR. There was no significant difference in clinical features between primary nonresponders and responders. Eight alleles were associated with PNR. A combined clinical-genetic model (AUROC, 0.87) more accurately predicted PNR compared with a clinical-only model (AUROC, 0.57; P < 0.0001). In an external cohort of 131 patients, increasing tertiles of PNR genetic risk score correlated with increased risk of PNR (P = 0.052). Twelve candidate loci were associated with DR. Genetic risk score quartiles for DR demonstrated a strong dose-response relationship in predicting treatment duration. Genetic risk scores for PNR and DR were not associated with infliximab levels or antibody formation. Conclusion: Genetic polymorphisms enhance prediction of PNR and DR to anti-TNF therapy in patients with UC.
Authors: Shaun Purcell; Benjamin Neale; Kathe Todd-Brown; Lori Thomas; Manuel A R Ferreira; David Bender; Julian Maller; Pamela Sklar; Paul I W de Bakker; Mark J Daly; Pak C Sham Journal: Am J Hum Genet Date: 2007-07-25 Impact factor: 11.025
Authors: Yago Gonzalez-Lama; Ignacio Fernandez-Blanco; Antonio Lopez-SanRoman; Carlos Taxonera; Begoña Casis; Susana Tabernero; Fernando Bermejo; Francisca Martinez-Silva; Juan Luis Mendoza; Pilar Martinez-Montiel; Jose Antonio Carneros; Fernando Sanchez; Jose Maté; Javier P Gisbert Journal: Hepatogastroenterology Date: 2008 Sep-Oct
Authors: Matthias Jürgens; Rüdiger P Laubender; Franziska Hartl; Maria Weidinger; Julia Seiderer; Johanna Wagner; Martin Wetzke; Florian Beigel; Simone Pfennig; Johannes Stallhofer; Fabian Schnitzler; Cornelia Tillack; Peter Lohse; Burkhard Göke; Jürgen Glas; Thomas Ochsenkühn; Stephan Brand Journal: Am J Gastroenterol Date: 2010-03-02 Impact factor: 10.864
Authors: M Pierik; S Vermeire; K V Steen; S Joossens; G Claessens; R Vlietinck; P Rutgeerts Journal: Aliment Pharmacol Ther Date: 2004-08-01 Impact factor: 8.171
Authors: Axel Dignass; James O Lindsay; Andreas Sturm; Alastair Windsor; Jean-Frederic Colombel; Mathieu Allez; Gert D'Haens; André D'Hoore; Gerassimos Mantzaris; Gottfried Novacek; Tom Oresland; Walter Reinisch; Miquel Sans; Eduard Stange; Severine Vermeire; Simon Travis; Gert Van Assche Journal: J Crohns Colitis Date: 2012-10-03 Impact factor: 10.020
Authors: Tanima De; Honghong Zhang; Cristina Alarcon; Bianca Lec; Juan Avitia; Erin Smithberger; Chuyu Chen; Minnie Horvath; Sara Kwan; Mary Young; Sarbani Adhikari; John Kwon; Jennifer Pacheco; Gail Jarvik; Wei-Qi Wei; Frank Mentch; Hakon Hakonarson; Patrick Sleiman; Adam Gordon; John Harley; Jim Linneman; Scott Hebbring; Loukia Parisiadou; Minoli A Perera Journal: Pharmacogenet Genomics Date: 2022-01-01 Impact factor: 2.089
Authors: Britt Roosenboom; Ellen G van Lochem; Jos Meijer; Carolijn Smids; Stefan Nierkens; Eelco C Brand; Liselot W van Erp; Larissa G J M Kemperman; Marcel J M Groenen; Carmen S Horjus Talabur Horje; Peter J Wahab Journal: Cells Date: 2020-04-06 Impact factor: 6.600